{
    "clinical_study": {
        "@rank": "11759", 
        "arm_group": [
            {
                "arm_group_label": "AZD2115 Dose 1", 
                "arm_group_type": "Experimental", 
                "description": "AZD 2115, Dose 1 administered as two inhalations BID"
            }, 
            {
                "arm_group_label": "AZD 2115 Dose 2", 
                "arm_group_type": "Experimental", 
                "description": "AZD 2115, Dose 2 administered as two inhalations BID"
            }, 
            {
                "arm_group_label": "Placebo MDI", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo MDI administered as two inhalations BID"
            }
        ], 
        "brief_summary": {
            "textblock": "This is a phase IIa dose-ranging, randomized, double-blind, chronic-dosing (14 Days),\n      three-period, placebo-controlled, multi-center, cross-over study to assess the efficacy and\n      safety of two dose levels of a dual pharmacology molecule with the combined properties of a\n      LAMA and a LABA (AZD2115) delivered by a metered-dose inhaler (MDI) in subjects with\n      moderate to severe chronic obstructive pulmonary disease (COPD)."
        }, 
        "brief_title": "Efficacy and Safety Study of Two Dose Levels of AZD2115 in Subjects With Moderate to Severe COPD", 
        "completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Chronic Obstructive Pulmonary Disease (COPD)", 
        "condition_browse": {
            "mesh_term": [
                "Lung Diseases", 
                "Respiration Disorders", 
                "Pulmonary Disease, Chronic Obstructive", 
                "Lung Diseases, Obstructive"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Chronic Obstructive Pulmonary Disease Diagnosis:  Subjects with an established\n             clinical history of COPD for more than 1 year at Screening, according to the COPD\n             GOLD guidelines.\n\n          -  Current or former smokers with a history of \u226510 pack years of cigarette smoking.\n\n          -  Post-bronchodilator FEV1/FVC ratio of <70%.\n\n          -  Pre-bronchodilator FEV1 must be <80% predicted\n\n          -  Women of non-child bearing potential (ie., physiologically incapable of becoming\n             pregnant, including any female who is 2 years post-menopausal); or women of child\n             bearing potential, has a negative serum pregnancy test at Screening  and agrees to\n             acceptable contraceptive methods for the duration of the study.\n\n        Exclusion Criteria:\n\n          -  Pregnancy:  Women who are pregnant or lactating.\n\n          -  Significant diseases other than COPD, ie., disease or condition which, in the opinion\n             of the Investigator, may put the subject at risk because of participation in the\n             study or may influence either the results of the study or the subject's ability to\n             participate in the study.\n\n          -  Primary diagnosis of asthma.\n\n          -  Alpha-1 antitrypsin deficiency as the cause of COPD\n\n          -  Other active pulmonary disease such as active tuberculosis, lung cancer,\n             bronchiectasis, sarcoidosis, idiopathic interstitial pulmonary fibrosis, primary\n             pulmonary hypertension, or uncontrolled sleep apnea.\n\n          -  Poorly controlled COPD (hospitalization due to poorly controlled COPD within 3 months\n             of Screening or requiring treatment with corticosteroids or antibiotics in the 6 week\n             interval prior to Screening or during Screening.\n\n          -  Unstable ischemic heart disease, left ventricular failure, or documented myocardial\n             infarction within 12 months of Randomization.\n\n          -  Clinically significant abnormal ECG."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "80 Years", 
            "minimum_age": "40 Years"
        }, 
        "enrollment": {
            "#text": "30", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 2, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02109406", 
            "org_study_id": "AZD2115 D3060C00006"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "AZD 2115 Dose 2", 
                    "Placebo MDI"
                ], 
                "description": "AZD 2115, Dose 1 administered as two inhalations BID", 
                "intervention_name": "AZD2115 Dose 1", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "AZD2115 Dose 1", 
                    "Placebo MDI"
                ], 
                "description": "AZD 2115, Dose 2 administered as two inhalations BID", 
                "intervention_name": "AZD 2115, Dose 2", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "AZD2115 Dose 1", 
                    "AZD 2115 Dose 2"
                ], 
                "description": "Placebo MDI administered as two inhalations BID", 
                "intervention_name": "Placebo MDI", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "May 29, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Clearwater", 
                        "country": "United States", 
                        "state": "Florida"
                    }, 
                    "name": "Pearl Therapeutics Study Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Charlotte", 
                        "country": "United States", 
                        "state": "South Carolina"
                    }, 
                    "name": "Pearl Therapeutics Study Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Spartanburg", 
                        "country": "United States", 
                        "state": "South Carolina"
                    }, 
                    "name": "Pearl Therapeutics Study Site"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "3", 
        "official_title": "A Randomized, Double Blind, Chronic Dosing (14 Days), Three Period, Placebo Controlled, Cross Over, Multi Center Study to Assess Efficacy and Safety of Two Dose Levels of AZD2115 MDI in Subjects With Moderate to Severe COPD", 
        "other_outcome": [
            {
                "description": "Cmax, AUC0-12, AUC0-t, tmax, Apparent elimination half-life (t1/2), Apparent volume of distribution (Vd/F), Apparent total body clearance (CL/F)", 
                "measure": "Pharmacokinetics", 
                "safety_issue": "No", 
                "time_frame": "Day 1 through Day 15"
            }, 
            {
                "description": "Safety will be assessed by AEs, physical examination findings, dry mouth and tremor assessments, paradoxical bronchospasm, vital signs, ECGs, and laboratory assessments.", 
                "measure": "Safety", 
                "safety_issue": "Yes", 
                "time_frame": "Day1 through Day 15"
            }
        ], 
        "overall_contact": {
            "email": "lfaria@pearltherapeutics.com", 
            "last_name": "Lori Faria", 
            "phone": "862-777-8047"
        }, 
        "overall_official": {
            "affiliation": "Pearl Therapeutics, Inc.", 
            "last_name": "Shahid Siddiqui, MD", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Forced expiratory volume in 1 second (FEV1) area under the curve from 0 to 12 hours (AUC0-12) relative to baseline", 
            "safety_issue": "No", 
            "time_frame": "14 Days"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02109406"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Change from baseline in morning pre dose trough FEV1", 
                "safety_issue": "No", 
                "time_frame": "14 Days"
            }, 
            {
                "measure": "Peak change in FEV1", 
                "safety_issue": "No", 
                "time_frame": "14 Days"
            }, 
            {
                "measure": "Forced vital capacity (FVC) AUC0-12 relative to baseline", 
                "safety_issue": "No", 
                "time_frame": "14 Days"
            }, 
            {
                "measure": "Peak change in FEV1", 
                "safety_issue": "No", 
                "time_frame": "Day 1"
            }, 
            {
                "measure": "Change from baseline in 12-hour post dose trough FEV1", 
                "safety_issue": "No", 
                "time_frame": "14 Days"
            }, 
            {
                "measure": "Time to onset of action", 
                "safety_issue": "No", 
                "time_frame": "Day 1"
            }
        ], 
        "source": "Pearl Therapeutics, Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Pearl Therapeutics, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "May 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}